We will use slides for our presentation today. The slides have been posted on our website and a link was sent to you separately by e-mail. Our comments today will be governed by our Safe Harbor statement, which in summary says that through the course of our presentation today we may make certain forward-looking statements and actual results may vary materially.So with that, I would like to turn the call over to Kevin. Kevin W. Sharer Thanks, Arvind, and good afternoon, everyone. As Arvind mentioned, this is hard to believe, my 77th and last Amgen quarterly conference call. I will make today a few comments, then step out of the room to leave Bob and his team to discuss the quarter and answer your questions. You may have noticed in the newspaper that our first CEO, George Rathmann, passed away over the weekend. I want to make a few comments about George. I can't say that I knew him well, but I did know him. He was certainly the most intense interviewer when I came here 20 years ago. And from that very first interview, his passion about biotechnology, his focus on the future and his love of Amgen all came through. We can't overstate his contribution to Amgen. What you read in the newspaper was accurate, but incomplete. His contribution centrality and enduring influence on us are everywhere. And his science base, his desire to make big bets on big products that can move the needle, his team leadership, his energy will always be part of us. In fact, today, Bob and I went out in front of the George Rathmann Laboratory where his statue stands and took some pictures. We'll miss George, but he'll always be here. Now I'd like to talk to my Amgen colleagues. As I do on each one of these calls, I want to thank you for delivering yet another excellent quarter. The results in revenue, net income, pipeline progress, business development and operations are all strong, thanks to your efforts. And I'd also like to say it's been a privilege to be your colleague and, for a while, to have a leadership role in this great enterprise. I'm deeply grateful for the opportunity and the experience. And to our colleagues who write about us, thank you for your interest, your effort, your perspective and your objectivity. While I did not always agree with all you said, I always respected you and you collectively have made us better. Thank you. And finally to our shareholders, we've always known who owned the company and who we worked for and who we're ultimately responsible to. We always try to listen, be transparent and fully trustworthy while delivering on our promises. Especially for those of you who have been with us for the long haul, we deeply appreciate your guidance, support and encouragement and sometimes patience. I've always felt we were partners. The company today is strong, capable and well positioned with a new team and leader who will lead us forward with the same sense of purpose, shared values, aspiration and effectiveness that have since George Rathmann's day characterized us and distinguished us.
In Bob, you'll have a superb human being and dedicated leader. I leave Amgen in a good place and good hands. Thank you, and my best to you all. Bob, it's all yours. Well, in 29 days it will be, but you can take the call.Read the rest of this transcript for free on seekingalpha.com